|
|
|
|
|
Print this page
|
|
Crescendo
|
(Protocol #EFC 5826; Randomized, multinational, multicenter, double blinded, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors )
|
|
The Crescendo Trial is a multi-center trial that will be enrolling up to 17,000 randomized patients at about 600 centers. The trial is sponsored by Sanofi-Synthelabo Recherche, the maker of rimonabant. The purpose of this study is to see whether an experimental drug called rimonabant, can help lower the chances of a patient having a heart attack, a stroke, or dying from a heart attack or stroke. It works on receptors (targets) in the brain and in the fat cells. Rimonabant may decrease weight and waist circumference (waist measurement) improving other conditions that increase the risk of heart attack and stroke. Patient participation in the study is anticipated to be approximately 50 months, just over 4 years.
|
Contant Info
Principal Investigator: Ronald P. Karlsberg, MD
Study Coordinator: : Maria Thottam, BS
Contact number: 310.275.9551
|
|
|
|
|